CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 24 filers reported holding CATABASIS PHARMACEUTICALS IN in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $407,000 | +114.2% | 508,415 | +156.8% | 0.01% | +100.0% |
Q2 2018 | $190,000 | -39.7% | 198,000 | +13.8% | 0.01% | -37.5% |
Q1 2018 | $315,000 | +21.6% | 174,000 | 0.0% | 0.01% | +14.3% |
Q4 2017 | $259,000 | -27.7% | 174,000 | +3.0% | 0.01% | -30.0% |
Q3 2017 | $358,000 | +111.8% | 169,000 | +40.8% | 0.01% | +100.0% |
Q2 2017 | $169,000 | +17.4% | 120,000 | +33.3% | 0.01% | +25.0% |
Q1 2017 | $144,000 | – | 90,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SV Health Investors, LLC | 2,857,667 | $4,572,000 | 5.05% |
Clarus Ventures, LLC | 2,752,488 | $4,404,000 | 3.28% |
SPHERA FUNDS MANAGEMENT LTD. | 388,030 | $621,000 | 0.12% |
Rhenman & Partners Asset Management AB | 310,756 | $497,000 | 0.08% |
BOSTON FAMILY OFFICE LLC | 24,467 | $39,000 | 0.01% |
OPPENHEIMER & CO INC | 90,000 | $144,000 | 0.00% |
Alyeska Investment Group, L.P. | 221,281 | $354,000 | 0.00% |
A.R.T. Advisors, LLC | 46,747 | $74,000 | 0.00% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 101,347 | $162,000 | 0.00% |
Acrospire Investment Management LLC | 680 | $1,000 | 0.00% |